We are live on ! Find out more

HKPD

Cellyan Biotechnology

HKPD

Market cap $5.51M

0.1118 USD

-0.0089

7.37%

At close Updated Sep 25, 4:00 PM EDT

Pre-market

After hours

0.1139

+0.0021

1.88%

1 day

-7.37%

5 days

-1.41%

1 month

-71.91%

3 months

-69.87%

6 months

-83.06%

Year to date

-86.14%

1 year

-93.57%

5 years

-96.04%

10 years

-96.04%

About: Cellyan Biotechnology Co Ltd is an integrated pharmaceutical cross-border e-commerce supply chain service provider with a professional team and related pharmaceutical storage facilities in Hong Kong. It operates through two main categories: OTC pharmaceutical cross-border e-commerce supply chain services, referred to as the Supply Chain Services division, and OTC pharmaceutical cross-border procurement and distribution, referred to as the Procurement and Distribution division. Its main business provides one-stop services for merchants engaged in cross-border pharmaceutical e-commerce, including OTC wholesale, import and export, warehousing, packaging, customs clearance and delivery to final destinations, forming a closed loop of pharmaceutical cross-border e-commerce supply chain.

Employees: 11

Healthcare Medical Distribution

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 0%

Neutral 100%

Negative 0%

Cellyan Biotechnology Co., Ltd Receives Nasdaq Notice of Additional Compliance Grace Period

HONG KONG, July 16, 2026 (GLOBE NEWSWIRE) -- Cellyan Biotechnology Co., Ltd (Nasdaq: HKPD) (the "Company"), a leading provider of over the counter (“OTC”) pharmaceutical cross-border e-commerce supply chain services in Hong Kong, today announced that it received a notification letter (the “Notification Letter”) on July 14, 2026 from Nasdaq's Listing Qualifications Department indicating that the Company has been granted an additional 180 calendar day period, or until January 11, 2027, to regain compliance with the Nasdaq's minimum $1.00 closing bid price requirement (“the Minimum Bid Price Requirement”) as set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on Nasdaq. To regain compliance with the Minimum Bid Price Requirement, the Company must maintain a closing bid price of the Company's Class A ordinary shares at least $1.00 per share for a minimum of ten consecutive business days on or prior to the end of the 180-day extension period, or January 11, 2027.

Cellyan Biotechnology Co., Ltd Receives Nasdaq Notice of Additional Compliance Grace Period

Cellyan Biotechnology Co., Ltd Receives Nasdaq Notice of Bid Price Deficiency

HONG KONG, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Cellyan Biotechnology Co., Ltd (Nasdaq: HKPD) (the "Company"), a leading provider of over the counter (“OTC”) pharmaceutical cross-border e-commerce supply chain services in Hong Kong, today announced that it received a notification letter (the “Notification Letter”) dated January 12, 2026 from Nasdaq's Listing Qualifications Department indicating that the closing bid price of the Company's class A ordinary shares of par value of US$0.001 each was below the minimum requirement of US$1.00 per share for 30 consecutive business days from November 26, 2025 through January 9, 2026, and the Company was therefore currently not in compliance with the minimum bid price requirement set forth under Nasdaq listing rule 5550(a)(2). The notification letter has no immediate effect on the listing of the Company's class A ordinary shares, which will continue to trade uninterrupted on Nasdaq under the ticker “HKPD”.

Cellyan Biotechnology Co., Ltd Receives Nasdaq Notice of Bid Price Deficiency

Hong Kong Pharma Digital Announced Results of 2025 Annual Meeting of Stockholders

HONG KONG, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Hong Kong Pharma Digital Technology Holdings Limited (NASDAQ: HKPD) ("HKPD" or the "Company"), a leading provider of over the counter (“OTC”) pharmaceutical cross-border e-commerce supply chain services in Hong Kong, today announced that all proposals at the Company's 2025 annual meeting of stockholders held on December 12, 2025 local time were duly passed. The shareholders of the Company passed and approved the following proposals:

Hong Kong Pharma Digital Announced Results of 2025 Annual Meeting of Stockholders

DCS Announces Q3 2025 Quarterly Financial Statements

San Diego, California--(Newsfile Corp. - December 1, 2025) - Direct Communication Solutions, Inc. (CSE: DCSI) (FSE: 7QU0), a leading provider of information technology solutions for the Internet of Things (IoT) market, is excited to announce Q3'2025 revenues of USD $2.0 million versus USD $1.6 million in Q2'2024 representing an increase of 28% year over year. The nine months revenues ending September 2025, were reported at USD $7.2 million versus USD $4.9 million in 2024 representing an increase of 47%.

DCS Announces Q3 2025 Quarterly Financial Statements

Hong Kong Pharma Digital Technology Holdings Limited Reports Financial Results for the Six Months Ended September 30, 2024

HONG KONG , March 28, 2025 /PRNewswire/ -- Hong Kong Pharma Digital Technology Holdings Limited (NASDAQ: HKPD) ("HKPD" or the "Company"), a leading provider of over the counter ("OTC") pharmaceutical cross-border e-commerce supply chain services in Hong Kong, today announced its unaudited financial results for the six months ended September 30, 2024. Financial Highlights for the Six Months Ended September 30, 2024: Net Revenues: The Company reported net revenues of $11, 091,189, an increase of 58.9% compared to $7,009,209 for the same period in 2023.

Hong Kong Pharma Digital Technology Holdings Limited Reports Financial Results for the Six Months Ended September 30, 2024

U.S. IPO Weekly Recap: Oil And Gas Well Equipment Provider Flowco Debuts, While More Sizable Deals Join The Pipeline

Three IPOs and three SPACs were listed this week. Eight issuers submitted initial filings this week, including a handful of sizable names. The US IPO market is set to host a historic event in the week ahead.

U.S. IPO Weekly Recap: Oil And Gas Well Equipment Provider Flowco Debuts, While More Sizable Deals Join The Pipeline

Hong Kong Pharma Digital Technology Holdings Limited Announces Closing of Initial Public Offering

NEW YORK , Jan. 16, 2025 /PRNewswire/ -- Hong Kong Pharma Digital Technology Holdings Limited ("Hong Kong Pharma" or the "Company") (NASDAQ: HKPD), a leading provider of over the counter ("OTC") pharmaceutical cross-border e-commerce supply chain services in Hong Kong, today announced the closing of its initial public offering (the "Offering") of an aggregate of 1,403,685 ordinary shares, par value $0.001 per share (the "Ordinary Shares") at a public offering price of US$4.00 per share of which 1,000,000 Ordinary Shares were offered by the Company, and 403,685 Ordinary Shares were offered by certain selling shareholders of the Company. Hong Kong Pharma did not receive any proceeds from the sale of ordinary shares by the selling shareholders.

Hong Kong Pharma Digital Technology Holdings Limited Announces Closing of Initial Public Offering

See News Rankings

Price charts implemented using Lightweight Charts™